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Evolution of Intrapulmonary Vascular Dilatations in Cirrhosis
To the Editor:
Intrapulmonary vascular dilatations (IPVD), diagnosed by
transthoracic contrast-enhanced echocardiography (CEE), can be
observed in 13% to 47% of individuals with liver cirrhosis.1,2 De-
spite the presence of IPVD, most patients are not characterized as
having hepatopulmonary syndrome (HPS), since the diagnosis of
this syndrome requires the presence of abnormal arterial oxygen-
ation (partial pressure of arterial oxygen  70 mm Hg, or alveolar
arterial oxygen gradient  20 mm Hg).3,4 One of the major con-
troversies is whether cirrhotic individuals with IPVD but without
changes in arterial oxygenation are affected by HPS in the early
phase and whether these alterations would appear during follow-
up.5 To our knowledge, there are no prospective studies of the
evolution of pulmonary parameters in cirrhotic individuals with
IPVD but without changes in arterial oxygenation. Would these
patients fulfill HPS criteria during follow-up?
In our series6 of 56 cirrhotic patients on a waiting list for ortho-
topic liver transplantation, the frequency of IPVD was 45% (25
patients). Among these patients, 16 (64%) did not fulfill the criteria
for HPS, confirming the high frequency of IPVD in cirrhotic sub-
jects without HPS. These patients were followed prospectively to
assess the evolution of pulmonary parameters. Of 16 cirrhotic pa-
tients with IPVD without changes in arterial oxygenation, 12 were
excluded from the study, 11 due to death (after exploratory lapa-
rotomy [1], cancer of the larynx [1], digestive hemorrhage [5],
spontaneous bacterial peritonitis [2], orthotopic liver transplanta-
tion [1 sepsis and 1 hemorrhage]) and 1 because he was submitted
to orthotopic liver transplantation. Mean follow-up of the excluded
patients was 13.8 months (2–28 months). The complementary
tests were not repeated in any of the excluded patients. Thus, the
final series consisted of 4 patients with a mean follow-up of 24
months (21–30 months). All patients were submitted to contrast-
enhanced echocardiography and measurement of arterial blood
gases at the beginning and at the end of follow-up. The results are
presented in Table 1. The contrast-enhanced echocardiography
remained positive in all patients. No patient presented significant
changes in arterial oxygenation that would characterize him as hav-
ing HPS. The present data suggest stability of the pulmonary pa-
rameters during the 2-year follow-up period.
The causes of the high mortality rate of our patients did not
seem to be related to the presence of HPS, both because of the
absence of pulmonary causes and because of the short period of
time between the diagnosis of IPVD and death. Schenk et al.7
demonstrated that not only the presence but also the severity of
HPS are related to the survival of cirrhotic patients. It should be
emphasized that our patients did not have HPS nor did they present
alterations in gas exchanges. In addition, our patients with HPS6
tend to have mild degrees of the syndrome, in contrast to the data
reported by Schenk et al.7 However, although this is unlikely, we
cannot exclude the possibility of progression to HPS in the patients
who died. In conclusion, the present results suggest that gas ex-
change abnormalities did not develop uniformly and IPVD per-
sisted during a mean follow-up of 24 months.
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Table 1. Blood Gas Measurements and Evaluation of IPVD in









PaO2 (mm Hg) Baseline 93.4 96.9 92.4 85.9
End 97.5 95.6 94.8 85.0
AaPO2 (mm Hg) Baseline 17.8 5.3 13.6 17.4
End 14.2 18.5 16.8 18
Abbreviations: PaO2, partial pressure of arterial oxygen; AaPO2, alveolar arterial
oxygen gradient.
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Long-Term Outcome of Hepatitis C in Children
To the Editor:
We have read with interest the paper by Casiraghi et al.1 conclud-
ing that hepatitis C virus (HCV) infection acquired early in life
(through blood transfusions) shows mild features and a slow progres-
sion during the first 35 years after exposure. Similar results came from
previous retrospective studies in adults transfused early in life for car-
diac surgery or for leukemia.
Chronic HCV infection is generally associated with mild liver dis-
ease during the first two decades of life in both transfused and perina-
tally infected children. Nevertheless, recent data in the literature and
our own experience suggest the need for caution regarding the prog-
nosis of HCV infection acquired in childhood. Regarding the short-
term prognosis, cases of severe hepatitis and cirrhosis can be seen
throughout childhood and adolescence in children without underlying
diseases. About 7% to 10% of Italian children with chronic hepatitis C
develop liver-kidney microsomal autoantibodies, and we could observe
that liver disease is more severe and progressive in these patients than in
a comparable population of HCV-infected children without serologi-
cal markers of autoimmunity.2 Also, we have recently seen 3 children
who had developed compensated cirrhosis in the first decade of life,
apparently in the absence of known comorbid conditions and autoim-
munity. All 3 were male, with alanine aminotransferase levels greater
than twice the normal throughout observation, and with history of
maternal drug abuse. Only one mother was coinfected with human
immunodeficiency virus (HIV). Birnbaum et al.3 reported 3 similar
cases, ages 4–11 years, but with decompensated cirrhosis and with
evidence of HIV coinfection in 2 of 3 mothers (abuse was not dis-
closed). Maternal HIV/HCV coinfection and maternal drug abuse are
independent risk factors for vertical HCV transmission; drug abuse
seems to favor HCV infection of maternal peripheral blood mononu-
clear cells, which in turn would transmit the infection from mother to
offspring.4 Whether these early events may have relevance on the outcome
of infection and disease remains to be elucidated. Nevertheless we are
closely following HIV-seronegative children with high alanine amino-
transferase levels and history of maternal abuse and/or HIV coinfection.
Regarding medium/long-term prognosis, it appears that older ad-
olescents and young adults have higher rates of liver fibrosis than do
younger children, independent of comorbid conditions, and we have
recently shown increasing rates of fibrosis in serial biopsies of children
on long-term follow-up.5 Casiraghi et al.1 show that virus replication is
maintained for decades in their patients; thus progression of liver dis-
ease could occur at any time, especially considering that exposure to
cofactors of liver damage increases in youth and adulthood.
Following these considerations, we hope that the apparently be-
nign profile of pediatric HCV infection will not discourage or delay
research in the therapy of this disease, taking into account that children
have a long life expectancy, and that an efficient and well-tolerated
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Reply:
We appreciate the letter of Bortolotti et al. and the update on their
results regarding the prognosis of hepatitis C virus (HCV) infection
acquired in childhood, either through transfusion or by the vertical/
perinatal route. We agree that hepatitis C is not always an innocuous
disease in childhood, and that cirrhosis and extensive fibrosis may
occur in some children even in the absence of comorbidities.1,2 The
authors indicate that liver disease may be more severe and progressive
in children with liver/kidney microsomal antibody type 1 autoanti-
bodies compared to those without serological markers of autoimmu-
nity.3 In addition, they suggest that maternal coinfection with human
immunodeficiency virus and HCV, as well as maternal drug use, both
independent risk factors for vertical transmission,4 might have a role in
worsening the outcome of HCV infection acquired perinatally.
Our data concern the long-term outcome (35 years) of HCV in-
fection in a unique cohort of individuals who acquired HCV through
mini blood transfusions derived from an HCV-infected donor.5 All
recipients were infected with the same virus genotype (1b), at the same
time (shortly after birth) and with the same volume of infectious blood
(21–30 mL), and were specifically traced through the clinical files of
the hospital in which they were born. None of our HCV-infected
individuals were liver/kidney microsomal antibody type 1 -positive
and none had comorbid conditions such as hepatitis B virus or human
immunodeficiency infection, or alcohol intake (50 g per day). More-
over, none of the individuals enrolled in this study were aware of
having been transfused and infected during the first weeks of life, and
only one (who was a drug user) had additional risk factors for HCV
infection. Therefore, it would seem that the differences in the outcome
of HCV infection acquired in childhood, observed in our and other
studies, may be due to differences in the population examined.
Taking into account the above findings, one could expect sub-
groups of children (i.e., those born to HCV-carrier mothers who are
coinfected with human immunodeficiency virus and/or are drug users,
and those with autoimmune abnormalities) who are at increased risk of
developing severe liver disease and even cirrhosis early in life. However,
the role of these determinants in heralding a more aggressive outcome
in HCV-positive children requires further investigation.
Finally, we fully agree with our colleagues that the apparent benign
course of HCV infection seen in most children does not imply that
treatment should be delayed or even unwarranted in childhood, and
that the research of novel, well-tolerated, and effective therapeutic
strategies should remain a priority.
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Does Noninvasive Staging of Fibrosis Challenge Liver Biopsy as a
Gold Standard in Chronic Hepatitis C?
To the Editor:
Liver biopsy is viewed as the gold standard for staging fibrosis in
chronic hepatitis. An ongoing great search for noninvasive diagnostic
tests aims at replacing this inconvenient and costly invasive procedure.
Several models have been proposed1–3-; however, most of them require
special laboratory parameters that are not available in clinical practice.
In a recent article, Wai et al. proposed a simple model on the basis of
routinely available laboratory test results (aspartate aminotransferase–
to-platelet ratio index, [APRI]), which was shown to predict with high
sensitivity and specificity liver fibrosis in patients with hepatitis C virus
infection.4 These results were recently challenged by Giannini and
Testa, who pointed out that the ratio of aspartate aminotransferase to
alanine aminotransferase assessed fibrosis more accurately than the
APRI.5
We would like to comment on the applicability and validity of
the APRI test, which we have applied to a large cohort of 484
treatment naive patients with chronic hepatitis C (271 males; mean
age, 46  0.4; range, 18-68 years). All patients underwent liver
biopsy as part of the screening evaluation within the course of
national or international clinical trials. Staging of fibrosis was done
according to the Scheuer6 score, which categorizes 4 different stages
of fibrosis (F0-F4), as compared to the Ishak score used by Wai et al.
referring to 6 stages (F0-F6).
Our results are in agreement with the data presented by Wai et al.,
although the overall sensitivity and specificity of the APRI as well as the
positive predictive value and the negative predictive value for the certain
cutoffs were found to be lower (Table 1). As mentioned, the different
histological scoring system (i.e., Scheuer vs. Ishak score) could be respon-
sible for these differences. Additionally, our results have been evaluated by
several pathologists, not by just one as in the Wai et al. study. Interobserver
differences certainly could have played a role in this respect, but in clinical
practice one is confronted with this kind of situation.
From these studies it appears that fibrosis stage assessed by
invasive and noninvasive approaches differ to some extent. In this
respect, sampling variability and the size of liver biopsies have to
be considered as important contributors to false fibrosis staging,7
and they raise the question of whether liver biopsy can still be
regarded as the gold standard for fibrosis assessment. Thus, the
interpretation of liver biopsy results on the background of a non-
invasive fibrosis prediction method should be proven as a rational
approach to improve accuracy of fibrosis staging. One should, how-
ever, be aware that a reliable noninvasive assessment of the different
stages of fibrosis cannot be made in all patients. Data by Wai et al.
as well as our data are in accordance, showing that a prediction
concerning presence or absence of significant fibrosis was possible
only in 57% and 51%, respectively, of the patients examined in
both studies.
Finally, the need to confirm histologically the stage of fibrosis is
suspect when clinical experience and laboratory data provide all nec-
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Reply:
We thank Berg et. al. for the interest expressed on our article.1
We are grateful that many investigators like Berg et. al. had tested
our prognostic model in their patient populations.2,3 Using the aspar-
tate aminotransferase to platelet count ratio index (APRI), significant
fibrosis could be identified or excluded in 57.5% of Berg’s patients
with 82% sensitivity and 93% specificity, and cirrhosis could be iden-
tified or excluded in 82.5% of patients with 69% sensitivity and 93%
specificity. The specificities were almost identical to those in our study,
while the sensitivities were lower. The proportion of patients who fell
into the classifiable group was higher than in our study. We agree that
the diminished sensitivities may be related to the use of a different
fibrosis scoring system, as well as multiple versus single pathologists
scoring the biopsies. It is also possible that the inclusion of stage 3 in
the Scheuer4 scoring system (fibrosis with architectural distortion but
no obvious cirrhosis) as cirrhosis may have affected the accuracy of
prediction of cirrhosis.
We agree that interobserver or intraobserver variability and size
of the biopsies may affect histological interpretation. Because liver
biopsies are not necessarily gold standards for assessing liver histol-
















For prediction of significant
fibrosis
0.50 168 (35) 122 (53) 46 (18) 82 (91)‡ 53 (47)‡ 66 (61)‡ 73 (86)‡
0.50 316 (65) 109 (47) 207 (82)
1.50 375 (77.5) 215 (93) 160 (63) 37 (41)‡ 93 (95)‡ 85 (88)‡ 57 (64)‡






For prediction of cirrhosis
1.0 325 (67) 286 (80) 39 (31) 69 (89)§ 80 (75)§ 55 (38)§ 88 (98)§
1.0 159 (33) 71 (20) 88 (69)
2.0 409 (84.5) 332 (93) 77 (61) 39 (57)§ 93 (93)§ 67 (57)§ 81 (93)§






1.0 325 (67) 310 (73.5) 15 (24) 76 (89)§ 73.5 (75)§ 30 (38)§ 95 (98)§
1.0 159 (33) 112 (26.5) 47 (76)
2.0 409 (84.5) 377 (89) 32 (52) 48 (57)§ 89 (93)§ 40 (57)§ 92 (93)§
2.0 75 (15.5) 45 (11) 30 (48)
Abbreviations: AST, aspartate aminotransferase; PPV, positive predictive value; NPV, negative predictive value.
*Results are given according to the APRI cutoff points proposed by Wai et al. to predict the absence (APRI  0.50) or presence (APRI 1.50) of significant fibrosis
and the absence (APRI 1.00) or presence (APRI 2.00) of cirrhosis.
†Staging of fibrosis was done according to the Scheuer score, which categorizes 4 different stages of fibrosis (F0, absent; F1, mild portal fibrosis without septa; F2,
moderate portal fibrosis with few septa; F3, numerous septa [bridging fibrosis] without cirrhosis; F4, cirrhosis), as compared to the Ishak score used by Wai et al. referring
to 6 stages (F0–F6). Significant fibrosis was defined as F2. Data for prediction of cirrhosis were given for patients histologically classified as either F3–F4 or F4.
‡§Respective data for sensitivity and specificity as well as the positive and negative predictive value assessed in the study by Wai et al. for patients with Ishak fibrosis
scores F0–2 vs. F3–6‡ and 5–6 vs. F0–4§ are shown in parentheses.
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ogy, noninvasive models will not have complete concordance with
histological staging. We agree that neither liver biopsy nor nonin-
vasive model is necessary when the severity of the patients’ chronic
liver disease is obvious, as in the case of patients with decompen-
sated cirrhosis. However, differentiating mild from moderate fibro-
sis, and moderate fibrosis from well-compensated cirrhosis may be
difficult even for experienced hepatologists. Thus, there remains a
role for simple noninvasive models that will help in providing more
reliable estimates of the stage of liver disease than a clinician’s
intuition.
CHUN-TAO WAI, M.D.
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High Sensitivity C-Reactive Protein Values Do Not Reliably Predict the Severity of
Histological Changes in NAFLD
To the Editor:
C-reactive protein is an acute phase reactant that has found wide-
spread application in clinical medicine as a predictor of cardiovascular
events.1 High sensitivity C-reactive protein (hsCRP) detects low-grade
systemic inflammation. Levels of hsCRP are raised in disorders associ-
ated with nonalcoholic fatty liver disease (NAFLD), including obesity2
and features of the insulin resistance syndrome (hypertriglyceridemia,
low HDL cholesterol, raised glucose level).3 In NAFLD, the differen-
tiation of simple steatosis from nonalcoholic steatohepatitis (NASH) is
clinically important. Steatosis alone tends to have a benign course,
whereas NASH may progress to cirrhosis, liver failure, and hepatocel-
lular carcinoma.4,5 At present, there is no specific clinical or biochem-
ical marker to distinguish the two entities. We therefore examined the
utility of hsCRP levels in differentiating simple steatosis from NASH,
and for predicting the severity of hepatic necroinflammation.
We measured hsCRP in 120 persons (IMMAGE CRPH, Beckman
Coulter, CA; lower detection limit  0.2 mg/L).6 Those with CRP
10 (n  12, including 3 with no necroinflammation) may have had
subclinical infections or minor traumas and were therefore excluded
from analysis.7 NASH (n  75) was distinguished from simple steato-
sis (n  33) by the presence of lobular inflammation, and either bal-
looning cells or perisinusoidal/ pericellular fibrosis in zone 3 of the
hepatic acinus.4 The severity of steatosis, necroinflammation and fi-
brosis were graded using the method of Brunt et al.8
Similar to previous reports, there were significant associations be-
tween the hsCRP levels and age (r  0.2, P  .01), body mass index
(r  0.5, P  .01), waist-to-hip ratio (r  0.4, P  .001), and insulin
resistance by homeostasis model (r  0.2, P  .04).7 However, no
relationship was discerned between the levels of hsCRP and the grades
of hepatic steatosis (r  0.2, P  .1), necroinflammation (r  0.1, P 
.4), and fibrosis (r  0.1, P  .5). The mean (SD) hsCRP for NASH
was 2.68  2.10 mg/L, and 2.23  1.68 mg/L for simple steatosis
(P  .4).
In this cohort, measurement of hsCRP was not useful in predicting
the histological severity of NAFLD. It has been shown that hsCRP
levels are strongly associated with body mass index and insulin resis-
tance,9 and 56% of our cohort were obese and insulin resistant. On the
other hand, the use of 3-hydroxy-3-methylalutaryl coenzyme A
(HMG-CoA) reductase inhibitors is known to reduce hsCRP levels,10
and 29% of our subjects were taking these agents. In the presence of
such confounders, the use of a multivariate model with a much larger
sample size is required to detect an effect of hepatic necroinflammation
on hsCRP levels. If the population parameters for hsCRP in patients
with NAFLD are similar to those observed in the present report, a
sample size of over 400 subjects per group will be required to have 80%
power to detect a statistically significant difference between simple
steatosis and NASH. Clearly, a multicenter collaborative approach is
needed to undertake such a study. However, we conclude that the
clinical utility of hsCRP is limited by the extent of overlapping values
in patients with NASH and simple steatosis.
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